Search Results

Displaying Results 751-775 of 10723 "'DRUG'"

Aug 14, 2026, 07:45 ET TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

initiating our in vivo POC studies for MDSC Inhibitors (Bi-specific antibody drug conjugates (ADCs)), potentially receiving orphan drug designation in Merkel cell carcinoma (MCC) for IFx-2.0, and potentially receiving orphan drug designation in AML for TBS-2025. The recent $50 million term credit facility

More news about: TuHURA Biosciences, Inc.

Aug 14, 2026, 07:01 ET Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update

FDA for the purpose of seeking their guidance on our plan to conduct a single phase 3 study and its acceptability as a pivotal trial for filing a New Drug Application (or NDA), the favorable outcome of which we provided in detail in our press release dated August 3, 2026.In

More news about: Acurx Pharmaceuticals, Inc.

Aug 14, 2026, 07:00 ET Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation

Evogene:Evogene Ltd. (Nasdaq/TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag chemical products. At the core of its technology is ChemPass AI™, a proprietary generative AI designed to explore vast chemical

More news about: Evogene

Aug 14, 2026, 06:34 ET ArkBio's RSV Antiviral Drug Ziresovir Receives FDA Approval for Phase II Clinical Trial

Journal of Medicine and The Lancet Child & Adolescent Health. In 2025, ziresovir was included as the only therapeutic drug in the WHO's Paediatric Drug Optimization for Respiratory Syncytial Virus publication. The newly approved phase II clinical trial marks the extension of ziresovir's

More news about: Shanghai Ark Biopharmaceutical Co., Ltd.

Aug 14, 2026, 06:08 ET ArkBio's RSV Antiviral Drug Ziresovir Receives FDA Approval for Phase II Clinical Trial

More news about: Shanghai Ark Biopharmaceutical Co., Ltd.

Aug 13, 2026, 21:12 ET /C O R R E C T I O N -- Longitude Rx/

are increasingly important as payers consolidate and shift financial risk onto providers, reimbursement compress, and cell-and-gene therapies reshape drug spending.Enzor joins Longitude Rx from Thyme Care, where she served as Vice President of Pharmacy Operations and led the Pharmacy Solutions team. Enzor's

More news about: Longitude Rx

Aug 13, 2026, 18:40 ET MDLN Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Medline Inc. (NASDAQ: MDLN) Investors to Contact the Firm

the Reuters article states that according to the FDA, Medline "failed to thoroughly investigate microbial contamination incidents in finished drug products and also cited inadequate cleaning practices."Why Did Medline's Stock Drop?Following the news of Medline's FDA

More news about: Kessler Topaz Meltzer & Check, LLP

Aug 13, 2026, 16:51 ET Perimeter Schedules Second Quarter 2026 Financial Results Conference Call for August 20th

ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Claire™, recently approved by the U.S. Food and Drug Administration (FDA), is our next-generation AI-enabled device. The Company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast

More news about: Perimeter Medical Imaging AI Inc.

Aug 13, 2026, 16:44 ET Atrium Therapeutics Reports Second Quarter 2026 Financial Results

therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. With the U.S. Food and Drug Administration's (FDA) recent clearance of its Investigational New Drug (IND) application for ATR 1072 for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome,

More news about: Atrium Therapeutics

Aug 13, 2026, 16:32 ET Shatterproof Applauds Massachusetts Effort to Restrict Dangerous Kratom Products and Protect Public Health

regulated like medications in the United States, and their strength, ingredients, and purity can vary widely. Health agencies, including the U.S. Food and Drug Administration, have raised concerns about adverse effects associated with kratom use, including substance use disorder, liver toxicity, seizures, respiratory

More news about: Shatterproof

Aug 13, 2026, 16:15 ET Nektar Therapeutics Announces Second Quarter 2026 Financial Results

development continue; (ii) rezpegaldesleukin, NKTR-0165, NKTR-0166 and NKTR-422 are investigational agents and continued research and development for these drug candidates is subject to substantial risks, including negative safety and efficacy findings in future clinical studies (notwithstanding positive findings

More news about: Nektar Therapeutics

Aug 13, 2026, 16:15 ET Aethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier® Program

enveloped viruses and extracellular vesicles has been demonstrated in both in vitro studies and human subjects.The Hemopurifier holds a U.S. Food and Drug Administration Breakthrough Device Designation for:The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant

More news about: Aethlon Medical, Inc.

Aug 13, 2026, 16:04 ET Inhibrx Reports Second Quarter 2026 Financial Results

quarter of 2027.In June 2026, the U.S. Food and Drug Administration (FDA) accepted for filing the Company's biologics license application (BLA) for the potential approval of ozekibart in conventional chondrosarcoma and assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027.The

More news about: Inhibrx Biosciences, Inc.

Aug 13, 2026, 16:01 ET Co-Diagnostics Reports Second Quarter 2026 Financial Results

10,000 PCR test runsSubmitted a 510(k) premarket notification, together with a concurrent CLIA Waiver by Application, to the U.S. Food and Drug Administration for the Co-Dx PCR Flu A/B & RSV test on the Co-Dx PCR Pro instrument, marking a significant regulatory milestone toward commercialization

More news about: Co-Diagnostics

Aug 13, 2026, 16:00 ET Four Vials Bought at Brooklyn Smoke Shop Fail Identity Testing

has not been approved for human use by the U.S. Food and Drug Administration or another regulatory authority.The FDA states that retatrutide cannot lawfully be used in compounding under federal law, is not a component of an FDA-approved drug and has not been found safe and effective for any condition.On

More news about: Peptide Critic

Aug 13, 2026, 16:00 ET Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results

mean ocular half-life in humans of 20 days, approximately three times longer than approved anti-VEGF therapies, and is designed to maintain effective drug levels in ocular tissues for longer. Zenkuda is being developed as a mainstay intravitreal biologic monotherapy that provides high immediacy, driven

More news about: Kodiak Sciences Inc.

Aug 13, 2026, 12:37 ET WSE Deadline Alert: SueWallSt Reminds Wise Group plc (WSE) Investors of Securities Class Action Deadline on September 29, 2026

involve more than half a billion euros ($582.5 million) in suspicious transactions, with alleged links to fraud, corruption, and drug trafficking. Prosecutors were reportedly finalizing a direct summons before the criminal court. The lawsuit contends that this risk was not disclosed

More news about: SueWallSt.com

Aug 13, 2026, 12:02 ET Pilot Project Between BioCytics and LIDE Biotech

network and access to patients to offer gold-standard as well as novel preclinical drug validation tools, including CDX and more than 2300 PDX models, covering 40+ cancer types. LIDE is unique with its 200+ primary or acquired drug resistant PDX models derived from patient samples, and its proprietary MiniPDX,

More news about: BioCytics Inc.

Aug 13, 2026, 11:02 ET Radnostix, Inc. Reports FY2026 2nd Quarter and Six Months Results - Completes Execution of FDA 483 & Recall Actions, Restores Capsule Inventory, Completes Lucerno Dynamics Asset Acquisition

products. Radnostix manufactures and supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer. Radnostix provides contract manufacturing of various drug products as well as radioisotope API supply for 3rd party theranostics clients. Radnostix manufactures

More news about: International Isotopes Inc.

Aug 13, 2026, 10:31 ET Bronchiectasis Market is Expected to Surge at a CAGR of 15% by 2036, Owing to the Launch of DPP1/CatC Inhibitors, Therapeutic Phage Cocktails, Nebulized Mucoactive Agents, and Other Novel Mechanisms | DelveInsight

11.2.1Drug Description11.2.2

More news about: DelveInsight Business Research, LLP

Aug 13, 2026, 10:30 ET Disposable Medical Sensors Market worth $16.13 billion by 2031 - Exclusive Report by MarketsandMarkets™

disposable biosensors across various diagnostic and monitoring applications, including glucose monitoring, infectious disease testing, pregnancy testing, drug and alcohol screening, and continuous glucose monitoring (CGM) systems. The growing prevalence of chronic diseases, increasing demand for rapid and

More news about: MarketsandMarkets

Aug 13, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR

information about joining the class action]In late 2024, Capricor submitted its Biologics License Application ("BLA") to the U.S. Food and Drug Administration for Deramiocel as a cell therapy for the treatment of Duchenne muscular dystrophy. In July 2025, the FDA issued a Complete Response

More news about: Pomerantz LLP

Aug 13, 2026, 10:00 ET Postal Service to Issue Commemorative Stamp for U.S. Coast Guard Academy Milestone

Guard Academy's primary training vessel since 1946, and USCGC Bertholf, a Legend-class national security cutter whose missions include maritime drug interdiction and securing the maritime border. Antonio Alcalá, an art director for USPS, designed this stamp with photographs courtesy of the U.S. Coast

More news about: U.S. Postal Service

Aug 13, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Wise Group plc of Class Action Lawsuit and Upcoming Deadlines - WSE

year and is nearing completion, concerns potential money laundering offences, with alleged links to fraud, corruption and drug trafficking" and that "[p]rosecutors are investigating whether Wise Europe's services were used by international criminal organisations, and are ⁠currently